Liver Augmentation: Techniques & Trade-Offs

Kinetic Growth Rate: When liver surgery candidates require resection but present with an insufficient future liver remnant, augmentation can stimulate contralateral hepatic growth a priori. Liver augmentation works by creating an atrophy-hypertrophy complex—inducing atrophy in the diseased hepatic lobe while driving compensatory hypertrophy in the remaining functional segment.

As Dr. Sameer Gadani explained in this ARRS Quick Bytes video, selecting the optimal technique depends on whether the clinical objective is rapid growth, long-standing procedural data, or concurrent tumor control during the hypertrophy phase.

• PVE: Portal vein embolization remains the traditional standard of care due to extensive clinical experience and historical safety data.
• LVD: Liver venous deprivation is the fastest emerging option for liver augmentation and highly safe when clinicians are experienced with embolic glue.
• Radiation Lobectomy: Deploys radioactive embolic beads via catheter to flood the target lobe, simultaneously treating the tumor while driving lobar fibrosis and contralateral hypertrophy.
  • A modified technique delivers a targeted high dose directly to the tumor-bearing segment before pulling back to flood the entire lobe, improving local tumor destruction and atrophy efficiency.
  • A meta-analysis (n=600) showed that only 30% successfully reached resection, accompanied by elevated postop morbidity, mortality, and dosimetry challenges.

The Test of Time: While radiation lobectomy requires more time to achieve target hypertrophy, this window acts as a natural biological filter; rapid tumor progression during this period indicates resection was unlikely to be beneficial.

• Monitoring the rate of hypertrophy serves as a vital marker for both underlying liver health and overall tumor aggressiveness.
• An upcoming trial will evaluate two-session functional MRI protocols to assess FLR function, overcoming insurance authorization challenges common with nuclear medicine scans.

RadFYI: Although PVE remains the benchmark and LVD offers rapid growth, radiation lobectomy provides a dual-action option—albeit requiring further trials beyond existing retro data.